$18.77

+0.88 (+4.92%)

Weekly Expected Move ±8.0%

$15 $17 $18 $19 $21

NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 36 · $2.2B mcap · 108M float · 1.27% daily turnover · Short 62% of daily vol

Credit Risk of going bust: lower than 84% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Immunome, Inc. would be worth roughly what it owes.
Total debt $4.6M against a stock market value of $2.21B.
Distance to default 11.03 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 61.1%; Altman Z'' 11.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE

29.2 / 100

NoneWeakNarrowWide

Primary source: Switching Costs · ROIC: -2208.4% · 5Y Avg: -402.2%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. IMNM has No discernible competitive edge (29.2/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. Negative ROIC of -2208.4% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

$24

Low

$30

Avg Target

$35

High

Based on 2 analysts since Aug 11, 2026 earnings

Analyst Recommendations

Strong Buy: 0Buy: 13Hold: 0Sell: 0Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$29.50

Analysts2

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-09-30	Stifel Nicolaus	Dara Azar	Initiated	$24	—	+11.6%	$21.51
2026-08-12	Wedbush	—	$33	$35	+2	+33.2%	$26.27
2026-05-28	Truist Financial	Supawat Thongthip	$36	$37	+1	+67.3%	$22.11
2026-05-28	Barclays	Lukas Shumway	Initiated	$36	—	+62.8%	$22.11
2026-05-15	Leerink Partners	Andrew Berens	$40	$33	-7	+49.9%	$22.02
2026-02-12	H.C. Wainwright	—	Initiated	$40	—	+70.9%	$23.41
2025-12-16	Lake Street	—	Initiated	$32	—	+36.8%	$23.39
2025-12-16	Evercore ISI	—	$18	$40	+22	+71.3%	$23.35
2025-12-15	Leerink Partners	—	Initiated	$40	—	+76.6%	$22.65
2025-12-01	Truist Financial	Karina Rabayeva	Initiated	$36	—	+95.4%	$18.42
2025-11-17	Stephens	—	Initiated	$33	—	+92.5%	$17.14
2025-09-05	Craig-Hallum	—	Initiated	$26	—	+147.1%	$10.52
2025-08-22	Evercore ISI	—	Initiated	$18	—	+74.8%	$10.30
2024-08-13	Piper Sandler	Biren Amin	Initiated	$23	—	+82.0%	$12.64
2024-04-15	Guggenheim	Michael Schmidt	Initiated	$35	—	+70.1%	$20.58
2024-04-01	Wedbush	David Nierengarten	Initiated	$33	—	+33.7%	$24.68

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+

Oct 27, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. IMNM receives an overall rating of C+. Strongest factors: D/E (4/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5), P/B (2/5).

Rating Change History

Date	From	To
2026-10-12	C	C+
2026-10-01	C+	C
2026-05-06	C	C+
2026-04-01	C+	C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+

Profitability

—

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

33.20

Safe Zone

Piotroski F-Score

4/9

✗ ✗ ✓ ✓ ✓ ✓ ✗ ✗ ✗

Beneish M-Score

—

Ohlson O-Score

0.52

Bankruptcy prob: 62.7%

High Risk

Credit Rating

A+

Score: 75.6/100

Trend: Stable

Earnings Quality

—

OCF/NI: 0.82x

Accruals: -10.6%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. IMNM scores 33.20, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. IMNM scores 4/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. IMNM's implied 62.7% bankruptcy probability signals significant financial distress. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. IMNM receives an estimated rating of A+ (score: 75.6/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

-7.39x

PEG

-0.44x

P/S

0.00x

P/B

4.05x

P/FCF

-10.96x

P/OCF

—

EV/EBITDA

-7.51x

EV/Revenue

—

EV/EBIT

-7.41x

EV/FCF

-8.60x

Earnings Yield

-10.60%

FCF Yield

-9.13%

Shareholder Yield

0.00%

Graham Number

—

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. IMNM currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

1.000

NI / EBT

Interest Burden

1.000

EBT / EBIT

EBIT Margin

—

EBIT / Rev

Asset Turnover

0.000

Rev / Assets

Equity Multiplier

1.085

Assets / Equity

ROE

-64.0%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. IMNM's ROE of -64.0% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

—

Price/Value

—

Margin of Safety

—

Premium

—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1524 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$18.77

Median 1Y

$13.06

5th Pctile

$2.92

95th Pctile

$58.13

Ann. Volatility

92.2%

Analyst Target

$29.50

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Clay Siegall, Ph.D. President, Chief Executive Officer and Chairman of the Board	$735,000	$—	$7,682,601
Max Rosett Financial ancial Officer	$472,500	$—	$2,785,557
Robert Lechleider, M.D. Chief Medical Officer	$530,300	$—	$2,747,618

CEO Pay Ratio

31:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $7,682,601

Avg Employee Cost (SGA/emp): $247,277

Employees: 177

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

177

+50.0% YoY

Revenue / Employee

$39,215

Rev: $6,941,000

Profit / Employee

$-1,199,966

NI: $-212,394,000

SGA / Employee

$247,277

Avg labor cost proxy

R&D / Employee

$984,921

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
ROE	-38.2%	-55.2%	-85.7%	-79.5%	-94.9%	-1.1%	-1.1%	-1.3%	-1.5%	-1.6%	-1.5%	-2.0%	-2.8%	-1.9%	-69.2%	-81.2%	-93.0%	-52.1%	-50.1%	-64.0%	-64.03%
ROA	-33.5%	-48.2%	-71.9%	-70.1%	-79.4%	-90.0%	-61.6%	-65.0%	-35.5%	-1.2%	-1.3%	-1.6%	-1.7%	-1.5%	-61.9%	-71.7%	-80.1%	-46.0%	-46.7%	-59.0%	-59.03%
ROIC	11.8%	27.4%	5.4%	6.8%	7.7%	8.6%	77.4%	73.4%	21.3%	5.2%	8.3%	9.9%	11.1%	7.7%	31.8%	-33.0%	39.3%	11.6%	-19.5%	-22.1%	-22.08%
ROCE	-39.1%	-52.3%	-86.7%	-1.2%	-1.6%	-2.2%	-1.3%	-1.8%	-32.4%	-22.7%	-15.4%	-28.3%	-51.4%	-82.5%	-57.0%	-69.7%	-76.2%	-34.2%	-38.4%	-48.0%	-48.02%
Gross Margin	—	—	—	—	—	—	-65.5%	-34.1%	95.3%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	82.1%	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	-1.9%	-1.4%	-1.3%	-24.7%	-128.6%	-16.9%	-17.4%	-30.3%	-15.3%	-11.6%	—	—	—	—	—
Net Margin	—	—	—	—	—	—	-1.8%	-1.3%	-1.2%	-24.2%	-125.8%	-15.3%	-16.2%	-29.3%	-14.2%	-10.8%	—	—	—	—	—
EBITDA Margin	—	—	—	—	—	—	-1.9%	-1.3%	-1.3%	-3.6%	-19.5%	-14.0%	-14.9%	-20.1%	-15.0%	-11.4%	—	—	—	—	—
FCF Margin	—	—	—	—	—	—	63.9%	56.3%	26.0%	-59.9%	-3.6%	-6.1%	-9.1%	-13.1%	-14.8%	-14.8%	-19.8%	-28.9%	-51.2%	—	—
OCF Margin	—	—	—	—	—	—	78.6%	64.1%	31.5%	-54.0%	-3.4%	-5.6%	-8.5%	-12.3%	-14.0%	-14.2%	-19.1%	-27.5%	-48.9%	—	—
ROE 3Y Avg	snapshot only																				-76.92%
ROE 5Y Avg	snapshot only																				-1.26%
ROA 3Y Avg	snapshot only																				-68.44%
ROIC Economic	snapshot only																				-40.34%
Cash ROA	snapshot only																				-36.93%
Cash ROIC	snapshot only																				-21.58%
CROIC	snapshot only																				-22.64%

Valuation

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
P/E Ratio	-13.88	-6.26	-2.12	-1.08	-1.46	-0.73	-2.06	-3.69	-4.64	-2.20	-1.10	-2.76	-2.88	-2.27	-2.61	-3.81	-4.62	-8.83	-11.02	-9.44	-7.390
P/S Ratio	—	—	—	—	—	—	25.72	14.56	10.00	16.75	20.06	67.25	86.90	73.66	48.86	64.28	106.41	270.32	616.26	—	0.000
P/B Ratio	5.30	3.21	1.82	1.29	2.33	1.61	4.39	10.33	16.77	1.96	0.89	2.86	4.10	3.68	1.74	3.01	3.90	2.96	4.20	4.57	4.049
P/FCF	-16.52	-8.45	-3.26	-1.52	-1.86	-0.93	40.23	25.85	38.39	-27.96	-5.56	-11.07	-9.51	-5.63	-3.31	-4.35	-5.36	-9.35	-12.04	-10.96	-10.956
P/OCF	—	—	—	—	—	—	32.70	22.70	31.76	—	—	—	—	—	—	—	—	—	—	—	—
EV/EBITDA	-11.42	-4.33	-0.81	-0.13	-0.74	-0.19	-0.57	-2.25	-0.53	-3.50	1.22	-6.32	-5.85	-3.00	-1.27	-2.90	-3.78	-5.69	-8.43	-7.51	-7.508
EV/Revenue	—	—	—	—	—	—	7.02	8.84	1.14	7.02	-4.23	41.70	63.46	50.15	20.29	43.32	78.66	176.73	472.06	—	—
EV/EBIT	-10.94	-4.20	-0.79	-0.12	-0.73	-0.18	-0.56	-2.20	-0.51	-3.42	1.20	-6.20	-5.75	-2.95	-1.25	-2.86	-3.73	-5.61	-8.32	-7.41	-7.411
EV/FCF	-13.32	-5.78	-1.24	-0.17	-0.93	-0.23	10.99	15.69	4.38	-11.71	1.17	-6.86	-6.94	-3.84	-1.37	-2.93	-3.96	-6.11	-9.22	-8.60	-8.603
Earnings Yield	-7.2%	-16.0%	-47.1%	-92.9%	-68.6%	-1.4%	-48.5%	-27.1%	-21.6%	-45.5%	-91.2%	-36.2%	-34.7%	-44.0%	-38.4%	-26.2%	-21.6%	-11.3%	-9.1%	-10.6%	-10.60%
FCF Yield	-6.1%	-11.8%	-30.7%	-65.8%	-53.9%	-1.1%	2.5%	3.9%	2.6%	-3.6%	-18.0%	-9.0%	-10.5%	-17.8%	-30.2%	-23.0%	-18.6%	-10.7%	-8.3%	-9.1%	-9.13%
Price/Tangible Book	snapshot only																				4.571
Shareholder Yield	snapshot only																				0.00%

Leverage & Solvency

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Current Ratio	7.88	5.82	4.77	4.36	3.97	3.09	1.87	1.50	3.96	6.63	10.18	7.12	6.17	4.08	10.49	12.13	8.90	14.69	21.68	15.08	15.077
Quick Ratio	7.88	5.82	4.77	4.36	3.97	3.09	1.91	1.51	3.96	6.63	10.18	7.12	6.17	4.08	10.49	12.13	8.90	14.69	21.68	15.08	15.077
Debt/Equity	0.00	0.01	0.01	0.01	0.01	0.02	0.02	0.05	0.06	0.01	0.01	0.01	0.01	0.03	0.02	0.02	0.02	0.01	0.01	0.01	0.009
Net Debt/Equity	-1.03	-1.02	-1.13	-1.14	-1.17	-1.20	-3.19	-4.06	-14.86	-1.14	-1.08	-1.09	-1.10	-1.17	-1.02	-0.98	-1.02	-1.02	-0.98	-0.98	-0.982
Debt/Assets	0.00	0.01	0.00	0.00	0.01	0.01	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.008
Debt/EBITDA	-0.00	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.06	-0.04	-0.04	-0.02	-0.03	-0.03	-0.02	-0.02	-0.02	-0.02	-0.02	-0.018
Net Debt/EBITDA	2.74	2.00	1.32	0.97	0.74	0.55	1.52	1.46	4.10	4.86	7.03	3.87	2.16	1.40	1.78	1.40	1.33	3.01	2.58	2.05	2.053
Interest Coverage	-1338.81	-2520.70	-3662.67	-4518.75	-7392.20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity Multiplier	1.14	1.20	1.26	1.29	1.32	1.44	3.47	4.44	15.33	1.24	1.12	1.17	1.20	1.33	1.12	1.10	1.13	1.08	1.05	1.08	1.077
Cash Ratio	snapshot only																				14.560
Cash to Debt	snapshot only																				113.338
FCF to Debt	snapshot only																				-47.752
Defensive Interval	snapshot only																				860.7 days

Efficiency & Turnover

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.16	0.16	0.16	0.07	0.06	0.06	0.05	0.03	0.04	0.03	0.02	0.01	0.00	0.000
Inventory Turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables Turnover	—	0.00	0.00	0.00	0.00	0.00	2.93	12.56	24.07	24.68	30.90	103.69	—	62.57	—	—	—	—	—	—	—
Payables Turnover	0.00	0.00	0.00	0.00	0.00	0.00	1.09	2.15	3.31	3.43	1.12	0.03	0.00	0.00	0.00	0.12	10.33	5.70	6.91	9.37	9.374
DSO	—	—	—	—	—	—	125	29	15	15	12	4	0	6	0	0	0	0	0	—	—
DIO	—	—	—	—	—	—	-38	-4	0	0	-25	-229	—	—	—	0	0	0	0	0	0.0 days
DPO	—	—	—	—	—	—	336	170	110	106	325	11814	—	—	—	2967	35	64	53	39	38.9 days
Cash Conversion Cycle	—	—	—	—	—	—	-249	-145	-95	-92	-339	-12039	—	—	—	-2967	-35	-64	-53	—	—
Fixed Asset Turnover	snapshot only																				0.000
Cash Velocity	snapshot only																				0.000

Growth (YoY)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue	—	—	—	—	—	—	—	—	—	—	4.4%	62.7%	-0.6%	-35.5%	-13.8%	16.7%	-4.4%	-23.2%	-63.3%	-1.0%	-1.00%
Net Income	—	-5.1%	-3.1%	-1.7%	-76.6%	-49.3%	9.1%	27.7%	40.6%	-1.9%	-6.9%	-9.0%	-12.9%	-1.7%	11.6%	19.1%	27.1%	27.5%	-9.5%	-19.7%	-19.75%
EPS	—	-4.2%	-2.6%	-1.6%	-73.8%	-46.9%	9.5%	28.1%	41.0%	-59.9%	-8.3%	-1.0%	-1.8%	4.0%	88.5%	44.3%	50.1%	48.0%	23.1%	8.0%	8.02%
FCF	—	-2.0%	-1.2%	-90.7%	-64.8%	-58.1%	1.1%	1.1%	1.1%	71.0%	-31.3%	-18.6%	-35.9%	-13.1%	-2.5%	-1.8%	-1.1%	-69.7%	-27.2%	-17.7%	-17.68%
EBITDA	—	-5.4%	-3.3%	-1.7%	-77.7%	-48.3%	9.7%	26.7%	39.6%	22.5%	-50.4%	-1.7%	-4.0%	-4.4%	-3.0%	-1.6%	-83.3%	-42.5%	-28.3%	-33.6%	-33.59%
Op. Income	—	-5.2%	-3.1%	-1.6%	-72.4%	-46.4%	9.8%	26.5%	38.7%	-2.0%	-7.0%	-9.2%	-13.0%	-1.8%	8.1%	17.3%	26.2%	26.7%	-9.5%	-20.4%	-20.42%
OCF Growth	snapshot only																				-16.85%
Asset Growth	snapshot only																				90.82%
Equity Growth	snapshot only																				95.00%
Debt Growth	snapshot only																				10.77%
Shares Change	snapshot only																				30.18%

Growth (CAGR)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	19.3%	—	—
Revenue 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gross Profit 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gross Profit 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Op. Income 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Op. Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
OCF 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
OCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Assets 3Y	—	—	—	—	—	—	—	—	—	49.4%	95.8%	66.5%	60.1%	60.7%	92.9%	96.6%	1.1%	2.1%	1.3%	1.4%	1.39%
Assets 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	72.7%	70.8%	54.5%	54.54%
Equity 3Y	—	—	—	—	—	—	—	—	—	42.6%	96.1%	61.2%	57.7%	55.5%	1.0%	1.1%	1.3%	2.4%	2.5%	2.8%	2.83%
Book Value 3Y	—	—	—	—	—	—	—	—	—	10.4%	98.2%	-7.2%	-8.0%	-10.6%	7.4%	7.4%	16.4%	74.2%	66.0%	82.3%	82.27%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue Stability	—	—	—	—	—	1.00	0.75	0.75	0.75	0.60	0.74	0.90	0.80	0.58	0.79	0.94	0.56	0.39	0.28	0.07	0.070
Earnings Stability	—	—	—	—	—	0.98	0.65	0.32	0.00	0.86	0.68	0.64	0.60	0.78	0.76	0.70	0.63	0.77	0.79	0.76	0.760
Margin Stability	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.000
Rev. Growth Consistency	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.000
Earn. Growth Consistency	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	0.00	0.00	0.000
FCF Positive Streak	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earnings Persistence	—	—	—	—	—	0.80	0.96	0.89	0.84	0.50	0.50	0.50	0.50	0.50	0.95	0.92	0.89	0.89	0.96	0.92	0.921
Earnings Smoothness	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ROE Trend	—	—	—	—	—	-1.91	-1.60	-2.09	-2.62	0.47	0.68	0.96	1.19	-0.06	0.80	1.13	1.67	0.92	0.36	0.43	0.427
Gross Margin Trend	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.06	0.68	-4.68	-6.84	-12.39	—	—
FCF Margin Trend	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-13.29	-12.03	-15.41	-22.06	-42.00	—	—
Sustainable Growth Rate	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Internal Growth Rate	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Cash Flow Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
OCF/Net Income	0.84	0.74	0.65	0.70	0.78	0.78	-0.06	-0.16	-0.15	0.07	0.18	0.23	0.28	0.38	0.74	0.84	0.83	0.90	0.87	0.82	0.821
FCF/OCF	1.01	1.00	1.00	1.01	1.01	1.01	0.81	0.88	0.83	1.11	1.07	1.08	1.07	1.07	1.06	1.04	1.04	1.05	1.05	1.05	1.049
FCF/Net Income	snapshot only																				0.861
CapEx/Revenue	—	—	—	—	—	—	14.7%	7.8%	5.4%	5.9%	22.8%	45.4%	63.1%	82.1%	81.6%	59.4%	73.0%	1.4%	2.2%	—	—
CapEx/Depreciation	snapshot only																				3.139
Accruals Ratio	-0.06	-0.13	-0.25	-0.21	-0.18	-0.20	-0.65	-0.76	-0.41	-1.15	-1.03	-1.20	-1.25	-0.94	-0.16	-0.11	-0.14	-0.05	-0.06	-0.11	-0.106
Sloan Accruals	snapshot only																				0.568
Cash Flow Adequacy	snapshot only																				-20.285

Dividends & Buybacks

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Payout Ratio	—	—	—	—	—	—	0.0%	0.0%	0.0%	—	—	—	—	—	—	—	—	—	—	—	—
Total Payout Ratio	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Net Buyback Yield	-13.6%	-0.1%	-0.4%	-0.7%	-0.1%	-0.1%	-0.1%	-0.0%	-0.1%	-3.7%	-87.0%	-30.6%	-51.8%	-72.7%	-78.0%	-51.4%	-22.1%	-34.1%	-19.3%	-20.0%	-19.96%
Total Shareholder Return	-13.6%	-0.1%	-0.4%	-0.7%	-0.1%	-0.1%	-0.1%	-0.0%	-0.1%	-3.7%	-87.0%	-30.6%	-51.8%	-72.7%	-78.0%	-51.4%	-22.1%	-34.1%	-19.3%	-20.0%	-19.96%

DuPont Factors

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Tax Burden (NI/EBT)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Interest Burden (EBT/EBIT)	0.98	0.98	0.98	1.00	1.00	1.00	0.99	0.98	0.97	3.72	5.20	3.62	2.73	1.91	1.15	1.11	1.09	0.97	0.99	1.00	1.000
EBIT Margin	—	—	—	—	—	—	-12.57	-4.01	-2.22	-2.05	-3.52	-6.73	-11.03	-16.97	-16.25	-15.13	-21.09	-31.48	-56.71	—	—
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.16	0.16	0.16	0.07	0.06	0.06	0.05	0.03	0.04	0.03	0.02	0.01	0.00	0.000
Equity Multiplier	1.14	1.14	1.19	1.13	1.20	1.26	1.85	2.03	4.24	1.26	1.23	1.28	1.58	1.29	1.12	1.13	1.16	1.13	1.07	1.08	1.085

Per Share

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
EPS (Diluted TTM)	$-1.75	$-2.07	$-2.68	$-2.98	$-3.05	$-3.04	$-2.42	$-2.14	$-1.80	$-4.87	$-22.51	$-4.38	$-5.07	$-4.67	$-2.58	$-2.44	$-2.53	$-2.43	$-1.99	$-2.25	$-2.25
Book Value/Share	$4.59	$4.04	$3.12	$2.50	$1.90	$1.37	$1.14	$0.77	$0.50	$5.46	$27.70	$4.24	$3.57	$2.89	$3.87	$3.09	$3.00	$7.26	$5.20	$4.64	$4.64
Tangible Book/Share	$4.59	$4.04	$3.12	$2.50	$1.90	$1.37	$1.14	$0.77	$0.50	$5.46	$27.70	$4.24	$3.57	$2.89	$3.87	$3.09	$3.00	$7.26	$5.20	$4.64	$4.64
Revenue/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.19	$0.54	$0.84	$0.64	$1.23	$0.18	$0.17	$0.14	$0.14	$0.14	$0.11	$0.08	$0.04	$0.00	$0.00
FCF/Share	$-1.47	$-1.53	$-1.74	$-2.11	$-2.39	$-2.39	$0.12	$0.31	$0.22	$-0.38	$-4.44	$-1.09	$-1.54	$-1.89	$-2.04	$-2.14	$-2.18	$-2.30	$-1.82	$-1.93	$-1.93
OCF/Share	$-1.46	$-1.53	$-1.74	$-2.09	$-2.38	$-2.37	$0.15	$0.35	$0.26	$-0.34	$-4.16	$-1.01	$-1.43	$-1.77	$-1.92	$-2.05	$-2.10	$-2.19	$-1.74	$-1.84	$-1.84
Cash/Share	$4.71	$4.12	$3.54	$2.86	$2.23	$1.68	$3.65	$3.15	$7.43	$6.29	$30.04	$4.64	$3.99	$3.47	$4.00	$3.08	$3.10	$7.48	$5.15	$4.59	$4.59
EBITDA/Share	$-1.72	$-2.05	$-2.66	$-2.93	$-3.01	$-2.99	$-2.39	$-2.13	$-1.81	$-1.28	$-4.25	$-1.19	$-1.83	$-2.41	$-2.21	$-2.16	$-2.29	$-2.47	$-1.99	$-2.22	$-2.22
Debt/Share	$0.00	$0.03	$0.02	$0.02	$0.02	$0.02	$0.02	$0.04	$0.03	$0.08	$0.16	$0.05	$0.05	$0.08	$0.06	$0.05	$0.05	$0.04	$0.03	$0.04	$0.04
Net Debt/Share	$-4.71	$-4.10	$-3.52	$-2.84	$-2.22	$-1.65	$-3.63	$-3.11	$-7.40	$-6.22	$-29.89	$-4.60	$-3.94	$-3.39	$-3.94	$-3.03	$-3.05	$-7.44	$-5.12	$-4.55	$-4.55

Academic Models

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	33.200
Altman Z-Prime	snapshot only																				60.416
Piotroski F-Score	2	2	2	1	1	1	4	4	5	5	5	4	3	1	3	4	3	4	4	4	4
Beneish M-Score	—	—	—	—	—	—	—	—	—	—	-8.22	-7.80	-5.04	-1.99	0.64	-2.09	—	—	—	—	—
Ohlson O-Score	snapshot only																				0.520
ROIC (Greenblatt)	snapshot only																				-48.53%
Net-Net WC	snapshot only																				$4.40
EVA	snapshot only																				$-214634850.00

Credit

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Credit Rating	snapshot only																				A+
Credit Score	59.35	60.99	36.96	32.20	32.93	44.33	51.68	51.76	52.15	71.19	73.57	76.30	76.10	64.71	76.05	76.16	75.87	75.70	75.71	75.58	75.581
Credit Grade	snapshot only																				5
Credit Trend	snapshot only																				-0.583
Implied Spread (bps)	snapshot only																				125.000
Industry Credit Rank	snapshot only																				76
Sector Credit Rank	snapshot only																				70

IMNM NASDAQ

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet